Status:
COMPLETED
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease
Lead Sponsor:
Duke University
Collaborating Sponsors:
UCB Pharma
Conditions:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Levetiracetam (Keppra) is used to treat partial onset seizures. Its biological effects suggest it might also be useful in treating 3 aspects of human motor neuron diseases (MNDs) for which no effectiv...
Detailed Description
Cramps in MNDs are believed to occur as a result of high-frequency burst firing of alpha motor neurons. Levetiracetam inhibits burst firing in epileptic rat hippocampus. Levetiracetam has never been t...
Eligibility Criteria
Inclusion
- Patients with MNDs (ALS, PLS or PMA)who have cramps with average severity 50/100 points, are able to provide informed consent, have normal renal function and are on a stable riluzole dose.
Exclusion
- Pregnancy; unstable medical illness, dementia; drug abuse or non-compliance
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00324454
Start Date
May 1 2006
End Date
June 1 2008
Last Update
June 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University ALS Clinic - 932 Morreene Road
Durham, North Carolina, United States, 27705